Barclays
CSTL icon

Barclays’s Castle Biosciences CSTL Stock Holding History

Barclays’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$723K Buy
30,330
+3,520
+13% +$78.4K ﹤0.01% 2982
2026
Q1 		$658K Sell
26,810
-45,339
-63% -$1.48M ﹤0.01% 3014
2025
Q4 		$2.81M Sell
72,149
-919
-1% -$29.6K ﹤0.01% 2679
2025
Q3 		$1.66M Sell
73,068
-36,675
-33% -$745K ﹤0.01% 3008
2025
Q2 		$2.24M Buy
109,743
+66,928
+156% +$1.24M ﹤0.01% 2756
2025
Q1 		$857K Sell
42,815
-6,198
-13% -$153K ﹤0.01% 3198
2024
Q4 		$1.31M Sell
49,013
-3,288
-6% -$100K ﹤0.01% 3195
2024
Q3 		$1.49M Buy
52,301
+39,567
+311% +$1.01M ﹤0.01% 3085
2024
Q2 		$277K Sell
12,734
-34,691
-73% -$773K ﹤0.01% 3390
2024
Q1 		$1.05M Buy
47,425
+8,045
+20% +$175K ﹤0.01% 3081
2023
Q4 		$850K Buy
39,380
+30,398
+338% +$535K ﹤0.01% 3562
2023
Q3 		$152K Sell
8,982
-528
-6% -$9.23K ﹤0.01% 3414
2023
Q2 		$130K Sell
9,510
-2,944
-24% -$59.7K ﹤0.01% 3454
2023
Q1 		$283K Buy
12,454
+5,866
+89% +$143K ﹤0.01% 3609
2022
Q4 		$155K Sell
6,588
-18,646
-74% -$432K ﹤0.01% 3985
2022
Q3 		$658K Buy
25,234
+24,040
+2,013% +$674K ﹤0.01% 2517
2022
Q2 		$26K Sell
1,194
-2,359
-66% -$54.8K ﹤0.01% 4291
2022
Q1 		$159K Buy
+3,553
New +$147K ﹤0.01% 3556

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Barclays's CSTL Position: Q2 2026 in Review

Barclays increased its Castle Biosciences (CSTL) stake by 13% in Q2 2026, buying an estimated $78.4K and bringing the position to 30,330 shares worth $723K. The position accounts for ﹤0.01% of the portfolio, ranked #2982.

Barclays first reported a position in CSTL in Q1 2022 and has held it in 18 quarters since. The position peaked at $2.81M in Q4 2025. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Barclays held 30,330 shares of Castle Biosciences worth $723K as of Q2 2026.
  • Barclays bought 3,520 Castle Biosciences shares in Q2 2026, an estimated $78.4K.
  • Castle Biosciences made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2982 holding.
  • Barclays first reported a position in Castle Biosciences in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Castle Biosciences position peaked at $2.81M in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.